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Abstract
Background: Chronic pruritus is a global clinical problem with a high impact on the quality of life and lack of specific
therapies. It is an excruciating and frequent symptom of e.g. uncurable renal, liver and skin diseases which often does not
respond to conventional treatment with e.g. antihistamines. Therefore antipruritic therapies which target physiological
mechanisms of pruritus need to be developed. Substance P (SP) is a major mediator of pruritus. As it binds to the neurokinin
receptor 1 (NKR1), we evaluated if the application of a NKR1 antagonist would significantly decrease chronic pruritus.
Methods and Findings: Twenty hitherto untreatable patients with chronic pruritus (12 female, 8 male; mean age, 66.7
years) were treated with the NKR1 antagonist aprepitant 80 mg for one week. 16 of 20 patients (80%) experienced a
considerable reduction of itch intensity, as assessed by the visual analog scale (VAS, range 0 to 10). Considering all
patients, the mean value of pruritus intensity was significantly reduced from 8.4 VAS points (SD +/21.7) before treatment
to 4.9 VAS points (SD +/23.2) (p,0.001, CI 1.913–5.187). Patients with dermatological diseases (e.g. atopic diathesis,
prurigo nodularis) had the best profit from the treatment. Side-effects were mild (nausea, vertigo, and drowsiness) and
only occurred in three patients.
Conclusions: The high response rate in patients with therapy refractory pruritus suggests that the NKR1 antagonist
aprepitant may indeed exhibit antipruritic effects and may present a novel, effective treatment strategy based on
pathophysiology of chronic pruritus. The results are promising enough to warrant confirming the efficacy of NKR1
antagonists in a randomized, controlled clinical trial.
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Introduction
Chronic pruritus is a frequent and globally occurring symptom of
systemic, dermatologic, neurological and psychiatric diseases [1–3].
It is currently estimated that 20 to 27% of all adults worldwide
endure chronic pruritus [4–6]. Since the symptom is regularly
characterized by a high intensity and long duration as well as by
cutaneous self-injury due to scratching, it has a high impact on the
quality of life and may lead to depression or even suicide of the
sufferers [4,7,8]. Given that pruritus was regarded for a long time as
subquality of pain [1], not much attention was paid to the
neurobiological basis of the symptom in the past. A second reason
forthe lackofpursuit ofspecifictreatmentstrategieswasowed tothe
assumption that treatment of underlying disease would automati-
cally relieve pruritus [2]. Therefore the mainstays of treatment for
chronic pruritus until to date are still antihistamines, topical and
systemic corticosteroids, or certain antidepressants [2]. However,
their efficacy is limited and systemic application of corticosteroids
and antidepressants may be associated with severe side-effects.
Recent studies have provided evidence that pruritus has a different
pathophysiology than pain and that it does not parallel the course of
the underlying disease [1,2]. Therefore we [9] and others [10] have
pursued the concept to develop target-specific treatments targeting
pathophysiological mechanism specific for pruritus. For example, in
2009, nalfurafine (which functions by activation of the spinal kappa-
opioid-receptor) was licensed in Japan as the first oral drug against
pruritus in hemodialysis patients [10]. Still, the development of new
and targeted antipruritic therapies against this excruciating and
frequent symptom not only in hemodialysis patients and for the
benefit of patients worldwide is mandatory.
Substance P (SP) is an important mediator in the induction and
maintenance of pruritus [11–13] and therefore represents an
interesting target for antipruritic treatment. SP is a tachykinin
which binds with different affinities to three neurokinin receptors
(NKR 1–3), but mainly to NKR1, which is expressed in the central
nervous system (CNS) and the skin [11]. We therefore investigated
in chronic pruritus patients the possible antipruritic potency of the
recently developed oral NKR1-antagonist aprepitant.
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Twenty patients (12 female, 8 male; age range: 36–85 years;
mean, 66.7 years; SD +/213.7; median 68.5 years) with therapy
refractory chronic pruritus (duration, 4 months to 20 years; mean,
61.3 months) were randomly selected for the treatment with the
selective high-affinity NKR1-antagonist aprepitant. Previous to
application of aprepitant, patients underwent clinical investigation
to determine the underlying origin of pruritus [3]. All patients had
been refractory to at least two (2 to 7) previous antipruritic
treatments with topical, intralesional or systemic corticosteroids,
antihistamines, and/or UV-irradiation. In 8 patients the origin of
chronic pruritus was unclear despite extensive laboratory and
radiological investigations (Table 1). In 12 patients underlying
diseases were found: chronic kidney disease (uraemic pruritus,
n=5), and a combination of multiple causal factors (chronic
kidney disease, diabetes mellitus, hyperuricaemia, and iron
deficiency, n=7). 10/20 patients had additionally an atopic
diathesis (four with pruritus of unknown origin and six with
pruritus of multifactorial origin). Clinically, 13/20 patients
suffered from severe scratch lesions (prurigo nodularis), while
seven patients reported chronic pruritus on clinically normal skin.
Patients received a monotherapy with aprepitant 80 mg once
daily for 3–13 days (mean, 6.6 days) without any other
concomitant antipruritic therapy. Patients recorded on a daily
base the average pruritus intensity on the visual analog scale (VAS)
ranging from 0 (no pruritus) to 10 (severe pruritus). In addition, at
the end of treatment, patients were interviewed on the total
percentage of change in pruritus (100% reduction = complete
relief of pruritus).
Patients’ data were anonymously statistically analysed with the
SPSS software package (Version 14.0, SPSS Inc., Chicago, Illinois,
USA). Paired T-test was applied and p values less than 0.05 were
considered statistically significant. Patients were treated individu-
ally with aprepitant and gave written informed consent to the off-
label application of the drug. The data were encoded in our
multidisciplinary pruritus database and retrospective analysis of
the study was authorized by the local ethics committee (ethics
committee of the medical association of Westphalia and medical
faculty of the Westphalian Wilhelms University Mu ¨nster).
Results
Sixteen out of 20 patients (80%) responded to short-term
aprepitant monotherapy. Four patients experienced complete
(100% reduction) or nearly complete (70–90%) cessation of
pruritus, eight patients reported on partial reduction (40–60%)
and four patients experienced weak reduction (10–30%) of
pruritus within the treatment period (mean, 50.6% pruritus
reduction). Four patients did not respond to the treatment.
Pruritus intensity on the VAS before treatment ranged from 5 to
10 (mean, 8.4 points; SD +/21.7; median VAS 8). After treatment
with aprepitant, pruritus intensity was reduced to a mean of 4.9
points (SD +/23.2; p,0.001; CI 1.913–5.187, Fig. 1). Patients
with dermatological diseases appeared to respond best to therapy
with aprepitant. Patients with atopic diathesis (n=10) or prurigo
Table 1. Collective of patients: demographic, clinical and response parameters.




Initial pruritus intensity on VAS
(ranging 0 (best) to 10 (worst))
Response: reduction
of pruritus in percent
1 68, f CP*, renal 2 60
2 82, m CP, renal 2 10 0
3 69, m PN*, renal 2 73 0
4 72, m CP, renal + 74 0
5 78, m CP, renal + 85 0
6 82, f PN, multifactorial (renal, hyperuricaemia) 2 10 20
7 66, f PN, multifactorial (renal, dry skin) + 54 0
8 55, f CP, multifactorial (cholestatic, dry skin,
psychosomatic factors)
+ 10 50
9 73, f PN, multifactorial (renal, diabetes) + 10 60
10 59, m PN, multifactorial (metabolic syndrome) 2 10 70
11 42, m PN, multifactorial (thyreoid dysfunction,
neurogenic)
2 89 0
12 66, f PN, multifactorial (hyperuricaemia, iron
deficiency)
+ 81 0 0
13 68, f PN, unknown + 10 0
14 77, f CP, unknown 2 10 0
15 81, f PN, unknown 2 71 0
16 85, f PN, unknown 2 10 10
17 36, m CP, unknown 2 84 0
18 52, f PN, unknown + 10 50
19 72, m PN, unknown + 65 0
20 50, f PN, unknown + 81 0 0
*CP, chronic pruritus; PN, prurigo nodularis.
+Atopic diathesis; +, present; 2, not present.
doi:10.1371/journal.pone.0010968.t001
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(p=0.001; Table 2). The mean reduction of pruritus in atopic
patients was 54% (p=0.001; CI 2.144–6.656, Fig. 1). Patients
without atopic diathesis (n=10) experienced weak reduction of
pruritus of 27% (p=0.048; CI 0.025–5.086, Fig. 1). In the group
of patients with prurigo nodularis, mean VAS reduction was
48.5% (p=0.001; CI 1.863–6.137, Fig. 1) ultimately also leading
to clinical improvement of scratch lesions. Patients without scratch
lesions showed pruritus reduction of 25.7% (p=0.094; CI-0.554–
5.554, Fig. 1). Patients with systemic origin of pruritus such as
chronic kidney disease (uraemic pruritus) responded only weakly
to aprepitant (mean reduction, 24.0%). However, patients with
uraemic pruritus and additional atopic diathesis showed a much
better response, reporting a mean reduction of pruritus of 50%.
Moreover, also prurigo nodularis patients responded better than
patients without scratch lesions in patient subgroups with the same
origin of pruritus (e.g., pruritus of unknown origin).
Interestingly, patients aged between 36 and 60 years (n=6)
responded significantly better (mean pruritus reduction,
66.7624.2%; median 60%) than elderly patients aged over 65
years (n=14; mean pruritus reduction, 29.3629.5%; median
25%; p=0.012). Gender analysis did not reveal a significant
difference in the response though men tend to respond better
(n=8; mean pruritus reduction, 46.3626.7%; median 45%) than
women (n=12; mean pruritus reduction, 36.7636.5%; median
30%; p=0.507).
In sum, therapy with aprepitant leads to pruritus reduction
mainly in dermatological diseases such as atopic diathesis and
prurigo nodularis. Side-effects remained mild (nausea, vertigo, and
drowsiness) and occurred in three patients. In none of these
patients cessation of aprepitant therapy was required.
Discussion
Our patients with chronic, yet therapy refractory pruritus,
experienced a significant, antipruritic effect (p,0.001) upon
monotherapy with the NKR1-antagonist aprepitant within one
week. This is the first clinical case series demonstrating that
targeting the neuropeptide SP via applying the NKR1-antagonist
aprepitant is an effective approach for the treatment of chronic
pruritus in patients who all had not responded to previous
therapies with topical, intralesional or systemic corticosteroids,
antihistamines, and/or UV-irradiation. Those patients who had
responded were extremely satisfied, gained new hope and
Figure 1. Distribution of values for pruritus intensity as scored on the visual analog scale (VAS) from 0 to 10 before (pre) and after
(post) aprepitant. Response is shown for all patients (All, n=20) as well as for several diagnostic subgroups: patients without (No Prurigo) or with
(Prurigo) clinical presence of chronic scratch lesions as well as patients with (AD) and without (No AD) atopic predisposition. Best antipruritic effects
were observed in patients with atopic predisposition and prurigo nodularis. Bar: median response in each group.
doi:10.1371/journal.pone.0010968.g001
Table 2. Antipruritic effects in patients with or without atopic diathesis.
Atopic diathesis
Pruritus in chronic kidney disease
number of patients/patients with
response
Multifactorial origin of pruritus
number of patients/patients with
response
Pruritus of unknown origin
number of patients/patients with
response Total Response
Present 2/2 4/4 4/3 9/10
Not present 3/0 3/2 4/1 3/10
doi:10.1371/journal.pone.0010968.t002
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long history of vexing pruritus and documentation of several futile
therapies. The most significant response rate was observed in
patients with atopic diathesis or clinical presentation of chronic
scratch lesions of prurigo nodularis. This is further supported by
previous findings of increased SP serum levels in patients with
atopic dermatitis, which correlated with the pruritus intensity [14].
Moreover, atopic dermatitis and prurigo nodularis were reported
to be characterized by increased SP-positive skin nerve fibers
[15,16], which might explain the high response rate in our patients
with these disorders. The observation of aprepitant exhibiting a
significant antipruritic activity particularly in inflammatory and
pruritic skin diseases was confirmed by a recent report.
Accordingly, upon treatment with aprepitant a rapid and
pronounced improvement was observed in three patients suffering
from cutaneous T-cell lymphoma [17]. The results in our patients
are promising enough to warrant assessing the efficacy of this
novel effect of aprepitant in a randomized, controlled clinical trial.
Most importantly, the antipruritic effect was already observed as
early as two days after initiating treatment. This rapid cessation of
chronic pruritus in patients with a long history of pruritus (mean,
61.3 months) argues against a placebo effect or spontaneous
remission in chronic pruritus patients who had not responded to
multiple pre-treatments. The early onset of action suggests that
aprepitant acts as a target-specific therapy. Experimental studies
clearly showed that SP is involved in pruritus induction in animals
and man [12,18]. Injected into the skin, SP rapidly induced
pruritus in both normal and experimentally-evoked inflamed skin
in non-atopic healthy volunteers [18]. In mice, SP injections
resulted in a dose-dependent increase in scratching of the injected
site [12]. The induction of pruritus is due to the SP-induced
production of pro-inflammatory cytokines and release of prurito-
genic mediators from mast cells such as histamine, tumor necrosis
factor (TNF)-a, prostaglandin D2, and leukotriene B4 via binding
of SP to NKR1 on keratinocytes and mast cells [13,19,20]. The
neutralization of these effects by aprepitant most likely suppresses
the release of pruritogenic mediators involved in induction and
maintenance of chronic pruritus. Moreover, previous experimen-
tal studies demonstrated that SP-antagonists may be beneficial
substrates for the treatment of inflammatory skin diseases in
animal models [21,22].
Aprepitant is a selective high-affinity NKR1-antagonist with
little or no affinity for other neurokinin receptors. It was developed
and approved in 2003 for the prevention of chemotherapy-
induced emesis and is usually administered for three days only
[23,24]. However, long-term application of the compound for up
to six or eight weeks was reported to be safe in a previous studies
[25]. Since in long-term studies usually 80 mg were applied, we
also decided to use this dosage. Thus, it needs to be investigated
whether increasing the dosage and/or the therapeutic interval may
increase the antipruritic effect. Aprepitant crosses the blood-brain
barrier to mediate antiemetic effects in the CNS, most likely in the
chemoreceptor trigger zone in area postrema at the base of the
fourth ventricle [23]. Although pruritus can be induced by SP
injection into the CNS in animals [26], recent central imaging
studies in humans showed that major cerebral areas for
pruriception are the somatosensory cortex, midcingulate gyrus,
and prefrontal area [27] but not the fourth ventricle. Therefore, it
may be speculated that the antipruritic effect of aprepitant is
mainly mediated in the skin but not in the CNS. This speculation
is underlined by the failure of pruritus relief in systemic diseases
such as chronic kidney disease upon application of aprepitant. Due
to a potential role of SP in depression and pain including
mediation of neurogenic dural inflammation, it was speculated
that aprepitant is effective in central and peripheral pain
syndromes [28]. However, aprepitant failed to relieve pain in
clinical and experimental studies such as the electrical hyperalgesia
model [29]. Clinical trials investigating the efficacy of aprepitant in
depression did not show significant benefit in safe, non-toxic doses
leading to interruption of development and approval of NKR1-
antagonists for this indication [26]. Recent studies clearly showed
separate pathways for itch and pain [1]. SP plays an important
role in both pain and pruritus pathways [1]. Interestingly, animal
studies suggest that the neuropeptides SP and calcitonin gene-
related peptide (CGRP) play an opposite role in pain and pruritus.
While enhanced SP levels have been demonstrated to be related to
reduced CGRP levels in an atopic dermatitis mouse model [30],
pain studies showed a correlation to CGRP levels [31]. It might
therefore be speculated that SP has a differential role in pain and
pruritus possibly explaining opposite response in pain (failure of
aprepitant) and pruritus (high response to aprepitant). It therefore
seems likely that application of an NKR1 antagonist in SP-
mediated pruritogenic diseases targets specific pruritus-related
neuronal pathways different from pain pathways.
In conclusion our findings outline that aprepitant presents a
novel, promising therapeutic approach of pruritus which is
especially effective in patients with chronic pruritus due to atopic
predisposition/dermatitis or prurigo nodularis. The tendency
towards better response in young (male) patients suggest aprepitant
to be a novel therapeutic option in adult but not elderly patients
with atopic dermatitis.
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